TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01658631

Intervention type: DEVICE
Intervention: arterial pressure measurement (Nexfin, a noninvasive finger cuff system)

Intervention type: DEVICE
Intervention: arterial pressure measurement (Nexfin, a noninvasive finger cuff system)
Study: NCT02504684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovenous 1920-nm diode laser
Description: Patients with saphenous veins treated with a new 1920-nm diode endolaser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous 1470-nm diode laser
Description: Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
Study: NCT02058693

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mixed salts amphetamine
Description: adjunctive to ADT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mixed salts amphetamine
Description: adjunctive to ADT
Study: NCT03585062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1,
Description: S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
Study: NCT03604744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.2 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 15 mg per os, single dose
Study: NCT03314142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with coarse wheat bran
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran and carob seed flour
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study: NCT03172208

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sc (multiple-dose)
Description: Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
Study: NCT01766856

Intervention type: OTHER
Intervention: Eustachian tube function testing
Description: Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
Study: NCT03679962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triple Chronotherapy
Description: Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
Study: NCT00100659

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon/ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon/ribavirin
Study: NCT03314142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran and carob seed flour
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran and carob seed flour
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran and carob seed flour
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread enriched with fine wheat bran and carob seed flour
Description: Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study: NCT02718118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dysport reconstituted at 1.5 mL (0.05 mL/injection)
Description: Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dysport reconstituted at 2.5 mL (0.08 mL/injection)
Description: Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
Study: NCT02555644

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Study: NCT00678106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Subjects weighing \> 60 Kg: 1 gram IV single dose Subjects weighing \< 60 Kg: 15 mg/Kg IV
Study: NCT02801630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PainShield SAW Patch Device
Description: The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PainShield SAW Patch Device
Description: The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
Study: NCT02575079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parafilm
Description: Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
Study: NCT01680419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mission Reconnect
Description: Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mission Reconnect
Description: Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
Study: NCT03604744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 15 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 15 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 15 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 15 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 30 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 30 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 30 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 30 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 30 mg per os, single dose
Study: NCT01680419

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREP
Description: The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREP
Description: The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others.
Study: NCT01742468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: long-chain n-3 PUFA
Description: Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sunflower oil
Description: Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
Study: NCT02541838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle power

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance perturbation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Study: NCT00828087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus Eluting Coronary Stent System
Description: Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chromium balloon expandable stent ( non drug eluting stent Arm)
Description: cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
Study: NCT01512641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary stage
Description: Kiddie-Schedule for Affective Disorders and Schizophrenia
Study: NCT04119557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC
Study: NCT01512641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary stage
Description: children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
Study: NCT00771030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Solution for subcutaneous or intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Solution for subcutaneous or intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Solution for subcutaneous or intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Solution for subcutaneous or intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: Solution for subcutaneous or intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous or intravenous administration
Study: NCT02578745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prophylactic NPWT (PICO system)
Description: The PICO NPWT system is a small, lightweight (\~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
Study: NCT00771030

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for subcutaneous or intravenous administration
Study: NCT02578745

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
Study: NCT04759534

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: protein convertase subtilisin/kexin type 9 inhibitor
Description: IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: protein convertase subtilisin/kexin type 9 inhibitor
Description: IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: protein convertase subtilisin/kexin type 9 inhibitor
Description: IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: protein convertase subtilisin/kexin type 9 inhibitor
Description: IBI306 is a kind of protein convertase subtilisin/kexin type 9 inhibitor.Received abdominal subcutaneous injection of IBI306 150 mg Q2W or 300 mg Q4W
Study: NCT01114997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine + Esmolol (Combo)
Description: Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)
Study: NCT00425555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Study: NCT01570712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOUSING FIRST PROGRAM
Description: Realization of a psychosocial organic evaluation and a citizen;~* Support in the development and the maintenance of the housing;~* Support in the diverse steps (administrative, judicial, financiers, etc.);~* Support around addictions / alcohol;~* Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~* to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional French services
Description: The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\\or the restoring, but this by means of the existing devices
Study: NCT04462718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrecuency
Description: EXPERIMENTAL GROUP: After the initial evaluation, the first 10 treatment sessions will be developed at the rate of five daily sessions in the first week, three sessions on alternate days in the second week and two sessions on alternate days in the third week (3 weeks in total), applying the monopolar capacitive diathermy with radiofrequency in the anterior aspect of the knee, in dynamic application in one of the members: affect or randomized (uni or bilateral pathology, respectively). This diathermy will be combined with a therapeutic exercise program supervised by a Physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: CONTROL GROUP: will be provided exclusively therapeutic exercises protocol to develop in the home setting that you must perform following a daily activity for three weeks. They will be evaluated at the end of that period and six moths later in order to have at least three timepoints to evaluate.
Study: NCT03057834

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle exercise
Description: Standardized pelvic floor muscle exercise regimen

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pelvic floor muscle exercise
Description: Standardized pelvic floor muscle exercise regimen
Study: NCT03121872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root Coverage Surgery with T-PRF
Description: Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root Coverage Surgery with CTG
Description: Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated